relacin: a RelA protein inhibitor and antibacterial agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 136264435 |
| CHEMBL ID | 3087702 |
| MeSH ID | M0584018 |
| Synonym |
|---|
| CHEMBL3087702 |
| 1357928-14-3 |
| mfcd26961072 |
| relacin |
| AS-35046 |
| AKOS037643743 |
| 2-[[2-[[(2r,3s,5r)-3-[[2-(carboxymethylamino)-2-oxoethyl]carbamoyloxy]-5-[2-(2-methylpropanoylamino)-6-oxo-1h-purin-9-yl]oxolan-2-yl]methoxycarbonylamino]acetyl]amino]acetic acid |
Relacin is a synthetic molecule that targets RelA, an essential protein in a conserved bacterial stress response system.
| Excerpt | Reference |
|---|---|
| "Relacin is a synthetic molecule that targets RelA, an essential protein in a conserved bacterial stress response system. " | ( Efficacy of relacin combined with sodium hypochlorite against Enterococcus faecalis biofilms. Dongmei, D; Hongyan, L; Wim, C; Xi, W; Yanling, C, 2018) |
| Excerpt | Reference |
|---|---|
| " The aims of this study were to evaluate the antimicrobial effect of relacin combined with sodium hypochlorite (NaOCl) on Enterococcus faecalis biofilms and to evaluate the cytotoxicity of relacin." | ( Efficacy of relacin combined with sodium hypochlorite against Enterococcus faecalis biofilms. Dongmei, D; Hongyan, L; Wim, C; Xi, W; Yanling, C, 2018) |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1055737 | Inhibition of Escherichia coli relA assessed as inhibition of (p)ppGpp synthesis at 1 mM by autoradiography in presence of [alpha32]GTP | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and structure-activity relationship of novel Relacin analogs as inhibitors of Rel proteins. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||